309. 進行性ミオクローヌスてんかん ［臨床試験数：4，薬物数：10（DrugBank：3），標的遺伝子数：4，標的パスウェイ数：9］
Searched query = "Progressive myoclonus epilepsy", "Unverricht Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03351569 | December 9, 2015 | 16 December 2017 | Intravenous Immunoglobulin for Unverricht-Lundborg Disease. | Intravenous Immunoglobulin for Unverricht-Lundborg Disease: Single-patient Trial. | Unverricht-Lundborg Disease | Drug: Intravenous immunoglobulin | Azienda Socio Sanitaria Territoriale di Mantova | Not recruiting | 18 Years | 25 Years | Male | 1 | Phase 3 | ||
| 2 | EUCTR2007-003210-33-FI | 03/08/2007 | 19 March 2012 | Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type | Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type | Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type MedDRA version: 9.1 Level: PT Classification code 10054895 Term: Baltic myoclonic epilepsy | Trade Name: Requip Product Name: Ropinirole hydrochloride Pharmaceutical Form: Tablet CAS Number: 91374208 Other descriptive name: ROPINIROLE HYDROCHLORIDE Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Department of Neurology, Turku University Hospital | Authorised | Female: yes Male: yes | 15 | Finland | ||||
| 3 | NCT00357669 | November 2006 | 25 May 2015 | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (=16 Years) With Genetically Ascertained Unverricht-Lundborg Disease | Unverricht-Lundborg Disease | Drug: Brivaracetam 25 mg;Drug: Brivaracetam 50 mg;Other: Placebo | UCB Pharma SA | Not recruiting | 16 Years | N/A | Both | 50 | Phase 3 | Finland;France;Italy;Netherlands;Réunion;Sweden;Tunisia | |
| 4 | NCT00368251 | November 2006 | 16 December 2017 | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease | Unverricht-Lundborg Disease | Other: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mg | UCB Pharma | Not recruiting | 16 Years | N/A | All | 56 | Phase 3 | United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro |